blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3193875

EP3193875 - LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  23.12.2022
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  14.01.2022
FormerGrant of patent is intended
Status updated on  14.09.2021
FormerExamination is in progress
Status updated on  19.08.2019
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  13.03.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Inflammatory Response Research, Inc.
515 E. Micheltorena, Suite G
Santa Barbara, CA 93103 / US
[2022/07]
Former [2018/11]For all designated states
Inflammatory Response Research, Inc.
515 E. Micheltorena, Suite G
Santa Barbara, CA 93103 / US
Former [2017/30]For all designated states
Inflammatory Response Research, Inc.
515 E. Micheltorena, Suite G
Santa Barbara CA 93103 / US
Inventor(s)01 / MAY, Bruce Chandler
515 E Micheltorena St STE G
Santa Barbara, CA 93103-4227 / US
 [2017/30]
Representative(s)Zacco Sweden AB
P.O. Box 5581
Löjtnantsgatan 21
114 85 Stockholm / SE
[N/P]
Former [2017/30]Zacco Sweden AB
P.O. Box 5581
114 85 Stockholm / SE
Application number, filing date15841696.611.09.2015
[2017/30]
WO2015US49767
Priority number, dateUS201462050668P15.09.2014         Original published format: US 201462050668 P
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016044095
Date:24.03.2016
Language:EN
[2016/12]
Type: A1 Application with search report 
No.:EP3193875
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.03.2016 takes the place of the publication of the European patent application.
[2017/30]
Type: B1 Patent specification 
No.:EP3193875
Date:16.02.2022
Language:EN
[2022/07]
Search report(s)International search report - published on:US24.03.2016
(Supplementary) European search report - dispatched on:EP24.04.2018
ClassificationIPC:A61K31/4965, A61K31/495, A61K31/47, A61K45/06, A61P25/00, A61P25/16, A61P25/28
[2018/21]
CPC:
A61K31/495 (EP,US); A61K31/47 (EP,US); A61K45/06 (US);
A61P25/00 (EP,US); A61P25/16 (EP,US); A61P25/28 (EP,US);
Y02A50/30 (EP,US) (-)
C-Set:
A61K31/47, A61K2300/00 (EP,US);
A61K31/495, A61K2300/00 (US,EP)
Former IPC [2017/30]A61K31/4965
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:LEVOCETIRIZIN UND MONTELUKAST IN DER BEHANDLUNG VON ENTZÜNDUNGSVERMITTELTEN STÖRUNGEN[2017/30]
English:LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLAMMATION MEDIATED CONDITIONS[2017/30]
French:LÉVOCÉTIRIZINE ET MONTÉLUKAST DANS LE TRAITEMENT DE TROUBLES MÉDIÉS PAR UNE INFLAMMATION[2017/30]
Entry into regional phase17.03.2017National basic fee paid 
17.03.2017Search fee paid 
17.03.2017Designation fee(s) paid 
17.03.2017Examination fee paid 
Examination procedure17.03.2017Examination requested  [2017/30]
17.03.2017Date on which the examining division has become responsible
14.11.2018Amendment by applicant (claims and/or description)
22.08.2019Despatch of a communication from the examining division (Time limit: M06)
20.02.2020Reply to a communication from the examining division
09.12.2020Despatch of a communication from the examining division (Time limit: M04)
15.04.2021Reply to a communication from the examining division
15.09.2021Communication of intention to grant the patent
11.01.2022Fee for grant paid
11.01.2022Fee for publishing/printing paid
11.01.2022Receipt of the translation of the claim(s)
Opposition(s)17.11.2022No opposition filed within time limit [2023/04]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
13.09.2019Renewal fee patent year 05
14.09.2020Renewal fee patent year 06
11.09.2021Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
MK16.02.2022
MT16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
[2024/41]
Former [2024/27]HU11.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
MK16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2024/21]HU11.09.2015
AL16.02.2022
AT16.02.2022
CY16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2024/18]HU11.09.2015
AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/42]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
BE30.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/35]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
IT16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
CH30.09.2022
LI30.09.2022
Former [2023/33]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
IE11.09.2022
LU11.09.2022
Former [2023/30]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
LU11.09.2022
Former [2023/22]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
MC16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2023/10]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SI16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2023/01]AL16.02.2022
AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/49]AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SK16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/48]AT16.02.2022
CZ16.02.2022
DK16.02.2022
EE16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/47]AT16.02.2022
DK16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RO16.02.2022
RS16.02.2022
SE16.02.2022
SM16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/46]AT16.02.2022
DK16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/42]AT16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
IS16.06.2022
PT16.06.2022
Former [2022/39]AT16.02.2022
ES16.02.2022
FI16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
Former [2022/36]AT16.02.2022
ES16.02.2022
HR16.02.2022
LT16.02.2022
LV16.02.2022
NL16.02.2022
PL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
GR17.05.2022
PT16.06.2022
Former [2022/35]ES16.02.2022
HR16.02.2022
LT16.02.2022
NL16.02.2022
RS16.02.2022
SE16.02.2022
BG16.05.2022
NO16.05.2022
PT16.06.2022
Former [2022/34]ES16.02.2022
LT16.02.2022
NL16.02.2022
NO16.05.2022
PT16.06.2022
Former [2022/33]LT16.02.2022
NO16.05.2022
Documents cited:Search[Y]US2004180868  (MULLALLY JOHN P [US]) [Y] 1-14 * paragraph [0047]; claim 7 *;
 [Y]US2005256131  (COESTER CARL-FR [DE]) [Y] 1-14 * claims 3-7 *;
 [Y]US2012263764  (WATSON RICHARD L [US]) [Y] 1-14 * paragraph [0133]; claims 17-19, 27-29 *;
 [Y]CN103505731  (UNIV CHINA PHARMA) [Y] 1-14 * abstract *;
 [Y]WO2014090990  (AIGNER LUDWIG [AT]) [Y] 1-14* page 13; claims 1-4 *
International search[Y]US2007225285  (HUTCHINSON JOHN H [US], et al) [Y] 3/1, 3/2, 4/1, 4/2, 15, 22 * ; paragraphs [0151], [0205], [0932] *;
 [XY]US2013085124  (MAY BRUCE CHANDLER [US]) [X] 1, 2, 5/1, 5/2, 17-19, 21, 23 * ; abstract; paragraphs [0006], [0007], [0034], [0035], [0059], [0063], [0076], [0080], [0098], [0099]; Claims 1, 12 * [Y] 3/1, 3/2, 4/1, 4/2, 6/1, 6/2, 15, 16, 20, 22;
 [Y]WO2013148366  (DUKE UNVERSITY [US]) [Y] 6/1, 6/2, 16, 20* ; paragraphs [0007], [0086] *
by applicantUS2004180868
 US2005256131
 US2012002637
 US2012263764
 US2013085124
 CN103505731
 WO2014090990
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.